{
  "id": "CD012380.PUB3",
  "draft": "Do treatments such as hydroxyurea (a medicine that reduces sickle cell crises) or ACE inhibitors (blood pressure medicines) help prevent or slow kidney disease in people with sickle cell disease (a blood disorder)?\n\n**Key messages**\n- Current studies do not provide clear evidence that hydroxyurea (a medicine that reduces sickle cell crises) or ACE inhibitors (blood‑pressure medicines) prevent or slow kidney disease (damage to the kidneys) in people with sickle cell disease (a blood disorder); there may be a small benefit for the kidneys' ability to concentrate urine (make urine more concentrated), but there was little or no difference in serious sickle‑cell‑related complications such as chest problems, painful episodes, or hospital stays, and no harmful effects were reported.\n- Evidence is also lacking for other potential treatments such as red blood cell transfusions (giving donated blood cells) and for older children and adults with sickle cell disease, because no suitable trials have been found for these groups.\n- More well‑designed, larger studies that follow patients for longer periods are needed to determine whether these medicines can truly protect kidney function (how well the kidneys work) in sickle cell disease and to assess any possible side effects.\n\n**Introduction**\nWhy are kidney problems a concern for people with sickle cell disease?\nSickle cell disease (SCD) is a genetic condition where the blood’s oxygen‑carrying protein is abnormal, causing red blood cells to become stiff and shaped like a sickle. These misshapen cells can block tiny blood vessels, leading to painful attacks and damage to many organs. One organ that is often affected is the kidney. Over time, the repeated blockage and reduced blood flow can hurt the tiny filtering units in the kidney, a problem called sickle cell nephropathy. This can show up early as tiny amounts of protein in the urine (microalbuminuria) and may progress to chronic kidney disease (CKD), where the kidneys no longer work well enough for at least three months. CKD can eventually lead to end‑stage renal disease, meaning the kidneys fail completely and dialysis or a transplant is needed. Because kidney damage can start in childhood and worsen with age, finding ways to protect the kidneys is a major health priority for people with SCD.\n\nWhat did the review authors want to find out?\nThe authors set out to discover whether any treatments can prevent or slow kidney damage in people with sickle cell disease. They looked at three types of interventions that are already used for other SCD problems:\n• Hydroxyurea – a medicine that reduces the number of sickle‑shaped cells.\n• Angiotensin‑converting enzyme inhibitors (ACEIs) – drugs that lower blood pressure in the tiny vessels of the kidney and are often used to protect kidneys in other diseases.\n• Red blood cell transfusions – giving healthy blood cells to replace the sickle cells.\nThe review asked: do any of these treatments, alone or together, improve kidney function, reduce protein loss in the urine, or lower the risk of serious kidney‑related complications? By summarising the best available trial evidence, the review aimed to tell patients, clinicians, and policymakers which strategies, if any, are effective and safe for protecting the kidneys of people with SCD.\n\n**Methods**\nWe searched for randomised controlled trials (studies that randomly assign participants to treatments) comparing interventions such as hydroxyurea, ACE inhibitors or transfusions with placebo or other care in people with sickle cell disease to prevent or reduce kidney complications; we pooled the results and assessed confidence in the evidence using standard criteria.\n\n**Results**\nWhat did we find?\nWe identified three randomised controlled trials that together enrolled 385 people with sickle‑cell disease. One trial compared hydroxyurea with placebo in 193 children aged about 9 to 18 months. A second trial compared the ACE‑inhibitor captopril with placebo in 22 adults who had normal blood pressure but microalbuminuria. The third trial compared the ACE‑inhibitor lisinopril with vitamin C in 170 children aged 1 to 18 years, also with normal blood pressure and microalbuminuria. The abstract did not give details about how long participants were followed, the countries where the studies were done, or who funded them.\n\nThe evidence is uncertain. It is unclear whether hydroxyurea improves kidney filtration in very young children, although it may slightly help the kidneys concentrate urine. Hydroxyurea probably makes little or no difference to serious complications such as acute chest syndrome, painful crises, or hospitalisations. It is also unclear whether ACE‑inhibitors reduce protein loss in the urine of adults or children with sickle‑cell disease, and whether they affect overall kidney function in adults.\n\n**Limitations**\nWe are not confident in the evidence because it is possible that people in the studies were aware of which treatment they were getting. Not all of the studies provided data about everything that we were interested in, the evidence does not cover all of the people or outcomes we are interested in, and the studies were very small.\n\n**Currency**\nThe abstract does not report a specific search date.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 845,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 35,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 24.142857142857142,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 28,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 28.0 to <13.0 (median)"
        },
        "active_voice": {
          "value": 80,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 40,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 17,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 266,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 266.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 50.474142011834346,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 12.216956889264583,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 13.539274725274723,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 11.55981065088757,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 16.284361792054103,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 52.78191039729501,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 6.914285714285715,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 13.908712114635714,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 13.9 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 7.606917666948436,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 343,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 343.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 140,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 140.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 242,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 242.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 845,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 845 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 0,
        "P50_count": 7,
        "P75_count": 5,
        "P90_count": 2,
        "P10_count": 0,
        "BEYOND_P90_count": 4,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 0,
        "P50_percentage": 38.88888888888889,
        "P75_percentage": 27.77777777777778,
        "P90_percentage": 11.11111111111111,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 22.22222222222222,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 27.77777777777778,
        "overall_assessment": "MODERATE CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The draft does not meet the required style rule that all subheadings be phrased as questions. Sections such as \"Key messages\", \"Methods\", \"Results\", \"Limitations\" and \"Currency\" are headings, not questions, which violates the Master Style Guide (5.3). Additionally, the text contains several clarity problems that would confuse patients:\n1. **Passive‑voice overload** – e.g., \"The evidence is uncertain. It is unclear whether hydroxyurea improves kidney filtration…\" (passive constructions make it hard to see who did what). The metrics show 28 passive instances (BEYOND_P90).\n2. **Long, dense sentences** – e.g., \"One trial compared the ACE‑inhibitor lisinopril with vitamin C in 170 children aged 1 to 18 years, also with normal blood pressure and microalbuminuria.\" (27 words, includes many clauses). The average words per sentence is 24.14 (P75) and the SMOG index is 13.9 (P90), indicating high reading difficulty.\n3. **Jargon without definition** – terms like \"microalbuminuria\", \"glomerular filtration rate\" and \"ACE‑inhibitor\" appear without simple explanations, which can alienate lay readers.\n4. **Noun‑heavy phrasing** – the draft has 266 nouns (BEYOND_P90) and 343 Dale‑Chall unfamiliar words, making the text noun‑dense and harder to follow.\n5. **Missing paragraph breaks and bullet formatting** – the \"Key messages\" list uses commas instead of dashes, and there are no blank lines between many sections, reducing readability.\n\nSuggested concrete rewrites:\n- Change subheadings to questions, e.g., \"What are the key messages?\", \"How did we find the studies?\", \"What did we find?\", \"What are the limitations of the evidence?\", \"How up‑to‑date is this review?\".\n- Replace passive sentences with active voice: \"We are unsure whether hydroxyurea improves kidney filtration…\" becomes \"We do not know if hydroxyurea improves kidney filtration…\".\n- Shorten long sentences: break the example above into two sentences and simplify numbers.\n- Define jargon: add brief explanations, e.g., \"microalbuminuria (tiny amounts of protein in the urine)\".\n- Use dash‑started bullet points for key messages and ensure blank lines between headings and paragraphs.\n\nThese changes will bring the draft into compliance with the style guide and improve patient‑friendly readability.\n\nMetrics summary: The draft meets word‑count limits (845 words) but shows significant deviations in passive voice (28, BEYOND_P90), noun count (266, BEYOND_P90), complex words (140, P90), Dale‑Chall unfamiliar words (343, BEYOND_P90) and long words (242, BEYOND_P90). These metric outliers support the editorial recommendations above.",
      "pls_evaluation_summary": "The PLS evaluation shows the draft is within the 850‑word limit but deviates markedly from typical PLS patterns: passive voice (28 instances, BEYOND_P90), noun count (266, BEYOND_P90), complex words (140, P90), Dale‑Chall unfamiliar words (343, BEYOND_P90) and long words (242, BEYOND_P90). Readability scores are borderline (Flesch Reading Ease 50.47, P75) but SMOG (13.9) and grade‑level indices are higher than the median, indicating the text is harder than usual for a plain‑language summary."
    }
  ]
}